RESUMEN
BACKGROUND/OBJECTIVES: BRCA1, BRCA2, ATM, and CHEK2 are known cancer predisposition genes (CPGs), but tumor risk in patients with simultaneous pathogenic variants (PVs) in CPGs remains largely unknown. In this study, we describe six patients from five families with multiple cancers who coinherited a combination of PVs in these genes. METHODS: PVs were identified using NGS DNA sequencing and were confirmed by Sanger. RESULTS: Families 1, 2, and 3 presented PVs in BRCA2 and ATM, family 4 in BRCA2 and BRCA1, and family 5 in BRCA2 and CHEK2. PVs were identified using NGS DNA sequencing and were confirmed by Sanger. The first family included patients with kidney, prostate, and breast cancer, in addition to pancreatic adenocarcinomas. In the second family, a female had breast cancer, while a male from the third family had prostate, gastric, and pancreatic cancer. The fourth family included a male with pancreatic cancer, and the fifth family a female with breast cancer. CONCLUSIONS: The early age of diagnosis and the development of multiple cancers in the reported patients indicate a very high risk of cancer in double-heterozygous patients associated with PVs in HR-related CPGs. Therefore, in families with patients who differ from other family members in terms of phenotype, age of diagnosis, or type of cancer, the cascade testing needs to include the study of other CPGs.
RESUMEN
OBJECTIVES: To compare real life effectiveness and safety of nivolumab in patients with non-small cell lung cancer (NSCLC), according to age and Eastern Cooperative Group performance status (ECOG-PS). METHODS: We performed a retrospective analysis of patients treated with nivolumab for NSCLC within a Belgian compassionate use program from July 2015 until December 2016. Safety and effectiveness were compared between patients aged ≥70â¯years andâ¯<â¯70â¯years and between ECOG-PS 0/1 andâ¯≥â¯2. RESULTS: A total of 324 patients with NSCLC were included. There was no significant difference between older (≥70) and younger (<70â¯years) patients with regards to progression free survival (PFS) (4â¯months (95%CI 2.6;4.8) versus 3.7â¯months (95%CI 1;7), pâ¯=â¯0.483) and overall survival (OS) (9.3â¯months (95% CI 5.5;13.1â¯months) versus 8.4â¯months (95%CI 6.3; 10.5), pâ¯=â¯0,638). Patients with an ECOG-PS ≥2 had a significant lower median PFS and OS compared to patients with an ECOG-PS 0-1 (2.2 (95%CI 1.4; 2.9) versus 5.6â¯months (95%CI 4.1; 7.1), pâ¯=â¯0.001 and 3.4 (95%CI 2.3; 4.5) versus 11.1â¯months (95%CI 8.9; 13.2), pâ¯<â¯0.001 respectively). No significant difference in all grades or grade 3/4 adverse events (AEs) were observed between the different age groups (pâ¯=â¯0.526 and pâ¯=â¯0.603 respectively). Patients with an ECOG-PS 0/1 had significantly more all grades AEs (pâ¯=â¯0.009) but no difference in grade 3/4 AEs was observed (pâ¯=â¯0.406) compared to ECOG-PS ≥2. CONCLUSION: This real life retrospective study confirms that safety and effectiveness of nivolumab is similar between different age groups, but that effectiveness is driven by performance status.